Human Immunodeficiency Virus | Access and Reimbursement | EU5 | 2016

The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and tolerability. Human Immunodeficiency Virus | Access & Reimbursement | EU5 content examines the market access factors that influence the success of HIV ARV therapies in the EU5 markets. The series is based on primary research with EU5 infectious disease specialists and internal medicine/general practitioner physicians, as well as country-specific payers.  This research explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific therapies at the brand level.

Login to access report